A Study Comparing User Experience of Different Delivery Devices for Glucagon

Phase 1

Completed

• Conditions: Healthy
• Interventions: Device: Nasal Glucagon Device (NG); Device: GEK; Drug: IM Glucagon

• Registration Number: NCT03765502
• Lead Sponsor: Eli Lilly and Company

Brief Summary

The purpose of the study is to learn more about different devices for delivering glucagon during simulations of severe hypoglycemic (low blood sugar) emergencies. The study will be carried out using medical manikins to simulate real life scenarios. No drug will be administered to humans. Part A will last approximately 17 days for Trained Users and Participants with Diabetes (PWD). Part B will last approximately nine (9) days for Untrained Users. Each part will be separated by approximately 7 days.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2018-11-16
• Study Start: 2018-11-19
• Study First Submitted QC: 2018-12-04
• Study First Posted: 2018-12-05
• Primary Completion: 2019-01-03
• Study Completion: 2019-01-03
• Status Verified: 2019-06
• Results First Submitted: 2020-01-06
• Results First Submitted QC: 2020-03-06
• Last Update Submitted: 2020-03-06
• Results First Posted: 2020-03-20
• Last Update Posted: 2020-03-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 99

Inclusion Criteria

All participants (Trained Users, Participants with Diabetes [PWDs] and Untrained Users):

• Are able to understand the purpose and procedure of the study and to give written informed consent to show willingness to participate in the study

Trained Users only:

• Are participants who are not diagnosed with Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM)
• Are close friends/relatives of a patient with T1DM or T2DM on insulin
• Have not previously administered any rescue medications (e.g. epinephrine, glucagon, narcan or seizure medications)

Untrained Users only:

• Have not been diagnosed with T1DM or T2DM, and are not a Trained User of a person with T1DM or T2DM
• Have not previously administered any rescue medications (e.g. epinephrine, glucagon, narcan or seizure medications)

Read More

Exclusion Criteria

All participants (Trained Users, PWDs and Untrained Users):

• In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study

Trained Users and Untrained Users only (i.e. the participants involved in the simulations):

• Are currently enrolled in a clinical study involving any type of medical research judged not to be scientifically or medically compatible with this study
• Are judged by the investigator as being likely to have difficulty performing the administration due to physical, cognitive and/or severe psychiatric disorder
• Are judged by the investigator as being trained or experienced in performing rescue drug administration
• Are judged by the investigator as being trained or experienced in performing high-fidelity simulations of drug administration
• Have received formal training in a medical field, and/or worked in this field within the prior 5 years; or otherwise are judged by the investigator as being trained or experienced as a first responder

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Nasal Glucagon Device (NG)	Nasal Glucagon Device (NG)	Empty NG device administered to a manikin during simulations of severe hypoglycaemia emergencies. No drug will be administered to humans.
Glucagon Emergency Kit (GEK)	GEK	Commercially available GEK delivered intramuscularly to a manikin during simulations of severe hypoglycaemia emergencies. No drug will be administered to humans.
Glucagon Emergency Kit (GEK)	IM Glucagon	Commercially available GEK delivered intramuscularly to a manikin during simulations of severe hypoglycaemia emergencies. No drug will be administered to humans.

Primary Outcome Measures

Name	Time	Method
Percentage of Trained Users That Performed a Successful Administration for Each Device	Part A: Days 8 - 9 and Days 15 - 17	Percentage of trained users who found both devices and performed a successful administration of both rescue devices for both simulations.

Secondary Outcome Measures

Name	Time	Method
Percentage of Untrained Users That Perform a Successful Administration for Each Device	Part B: Day 1 and Days 8-9	Percentage of untrained users who found both devices and performed a successful administration of both rescue devices for both simulations.
Average Time for Trained Users to Successfully Administer One Device Over the Other	Part A: Day 8 and Days 15-17	Average time for trained users who found both devices to successfully administer one rescue device over the other in Part A.
Average Time for Untrained Users to Successfully Administer One Device Over the Other	Part B: Day 1 and Days 8-9	Average time for untrained users who found both devices to successfully administer one rescue device over the other in Part B. To successfully administer either NG or GEK, a participant must complete all of the critical steps for each device, and administer a complete dose.
Percentage of Participants (Trained and Untrained Users) That Prefer One Device Over the Other	Part A: Days 8-9; Day 15-17 and Part B: Day 1; Days 8-9	Overall preference was measured via the Rescue Device Preference (RDP) questionnaire completed by Trained and Untrained participant users. Participants rated their preference for NG or GEK by choosing one of five radio buttons: Strongly prefer NG, prefer NG, no preference, prefer GEK, strongly prefer GEK. Data here represents pooling for Part A and Part B.
Percentage of Participants (PWD) That Prefer One Device Over the Other	Part A: Days 15 - 17	Preference was measured by the PWD overall feeling of being safer during a severe low blood sugar event using Rescue Device Preference-Associated Person (RDP-AP). Participants rated their preference for NG or GEK by choosing one of five radio buttons: Strongly prefer NG, prefer NG, no preference, prefer GEK, strongly prefer GEK.
Percentage of Participants Trained and Untrained Users That Find One Device Easy to Use Over the Other	Part A: Days 15 -17 and Part B: Days 8 - 9	Ease of use was measured via the Individual Rescue Device Ease of Use (RDEU) Questionnaire by Trained and Untrained Participants. Participants answered three questions about ease of use for each device by choosing one of five radio buttons: Strongly disagree, disagree, neither disagree nor agree, agree, strongly agree. Data here represents pooling of Simulation 1 for Part A and Part B.

Trial Locations

Locations (1)

High Point Clinical Trials Center; 🇺🇸 High Point, North Carolina, United States